Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Implications of the Doha Declaration on the Trips Agreement and Public Health - Health Economics and Drugs Series No. 012
(2002; 56 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentForeword
View the documentAcknowledgements
View the documentAbbreviations and acronyms
View the documentExecutive summary
View the documentIntroduction
View the documentScope
View the documentThe role of TRIPS and IPRs
Open this folder and view contentsPublic health measures
Open this folder and view contentsFlexibility in TRIPS
Open this folder and view contentsMembers with insufficient or no manufacturing capacities
View the documentTransfer of technology to LDCs
View the documentExtension of transitional period for LDCs
View the documentSpecial treatment under TRIPS
View the documentLegal status of the Doha Declaration
View the documentIssues not covered in the Declaration
View the documentConclusions
View the documentAnnex 1 - Doha Declaration on the TRIPS Agreement and Public Health
View the documentAnnex 2 - Levels of development of pharmaceutical industry, by country
View the documentReferences


1. Abbott F. The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO. Journal of International Economic Law, Oxford University Press, 2002.

2. Abbott F. Compulsory Licensing for Public Health Needs. The TRIPS Agenda at the WTO after the Doha Declaration on Public Health. Occasional Paper 9. Geneva, Quaker United Nations Office, 2002.

3. Attaran A. The Doha Declaration on the TRIPS Agreement and Public Health: Options for TRIPS Council. Paragraph 6. Working Draft, 2002.

4. Ballance R, Pogány J, Forstner H. The World’s Pharmaceutical Industry. An International Perspective on Innovation, Competition and Policy. Vienna, United Nations Industrial Development Organization, 1992.

5. Bond P. Globalization, Pharmaceutical Pricing and South African Health Policy: Managing Confrontation with U.S. Firms and Politicians. International Journal of Health Services, 23 March 1999.

6. Correa C. Intellectual Property Rights, the WTO and Developing Countries. The TRIPS Agreement and Policy Options. London and New York, Zed Books, 2000.

7. Correa C. Implementing National Public Health Policies in the Framework of the WTO Agreements. Journal of World Trade, 2000, vol. 34, no. 5.

8. Correa C. Integrating Public Health Concerns into Patent Legislation in Developing Countries. Geneva, South Centre, 2000, p.22.

9. Correa C. Protection of Data Submitted for the Regulation of Pharmaceuticals. Implementing the Standards of the TRIPS Agreement. Geneva, South Centre, 2002.

10. Correa C. Trends in Drug Patenting. Case Studies. Buenos Aires, Corregidor, 2001.

11. Chirambo M. The International Patent System. Regional Approaches. Paper presented at the WIPO Conference on the International Patent System. Geneva, 25-27 March 2002.

12. Drahos P. Developing Countries and International Intellectual Property Standard-Setting. Study prepared for the UK Commission on Intellectual Property Rights. 2002. Available from URL: http://www.iprcommission.org

13. Engelberg A. Implementing the Doha Declaration. A Potential Strategy for Dealing with Legal and Economic Barriers to Affordable Medicines. 2002. Available from URL: http://www.cptech.org/ip/health/pc/engelberg.html

14. European Commission (DG1). Note for the Attention of the 113 Committee (Deputies), 5 October 1998. Subject: WTO TRIPS/World Health Organization - Revised Drug Strategy. Meeting of the Ad Hoc Working Group, 13-16 October 1998.

15. European Commission. WTO Ministerial Declaration on the TRIPS Agreement and Public Health. Brussels, European Commission, 19 November 2001.

16. European Commission. Tiered Pricing for Medicines Exported to Developing Countries, Measures to Prevent their Re-importation into the EC Market and Tariffs in Developing Countries. Working Document. Brussels, European Commission (DG Trade), 22 April 2002.

17. Gillespie-White L. What Did Doha Accomplish? 2001. Available from URL: http://mail.iipi.org/db/views/detail.asp?itemID=21

18. Harmon A, Pear R. Canada Overrides Patent for Cipro to Treat Anthrax. New York Times, 19 October 2001.

19. International Intellectual Property Institute. Patent Protection and Access to HIV/AIDS Pharmaceuticals in Sub-Saharan Africa. Washington D.C., International Intellectual Property Institute, 2000.

20. Jackson J. The Jurisprudence of GATT and the WTO. Cambridge, Cambridge University Press, 2000.

21. Kettler H. Using Intellectual Property Rights Regime to Meet Global Health Needs. Commission on Intellectual Property Rights, 2002. Available from URL: http://www.ciprcommission.uk

22. MSF. Fatal Imbalance. The Crisis in Research and Development for Drugs for Neglected Diseases Geneva, Médecins Sans Frontières, 2001.

23. OXFAM. TRIPS and Public Health. The Next Battle. London, OXFAM, 2002.

24. Raja K. Health Declaration Gives Green Light to Put Public Health First. Third World Economics. Trends and Analysis, 2001, issue 268, no.1.

25. Reichman J. From Free Riders to Fair Followers: Global Competition Under the TRIPS Agreement. New York University Journal of International Law and Politics, 1997, vol. 29, no. 1-2.

26. Reichman J. Patents and Public Health in Developing Countries: Bargaining Around the TRIPS Impasse. Paper presented to the Conference on Access to Essential Medicines, University of Wisconsin School of Law, 8-10 March 2002.

27. South Centre. AIDS and Anthrax: Strange Bedfellows? South Letter, 2001, vols 3 & 4.

28. ‘t Hoen E. The Declaration on TRIPS and Public Health: A Step in the Right Direction. Bridges, 2001, year 5, no. 9.

29. ‘t Hoen E. TRIPS, Pharmaceutical Patents and Access to Essential Medicines: A Long Way from Seattle to Doha. Chicago Journal of International Law, vol. 3, no. 1, Spring 2002.

30. Thorpe P. Study on the Implementation of the TRIPS Agreement by Developing Countries, Study prepared for the UK Commission on Intellectual Property Rights, (forthcoming 2002).

31. UNCTAD. The TRIPS Agreement and Developing Countries. Geneva, United Nations Conference on Trade and Development, 1996.

32. Vandoren P. Clarification of the Relationship between TRIPS and Public Health Resulting from the WTO DOHA Ministerial Declaration. The Journal of World Intellectual Property, vol. 5, no. 1, January 2002.

33. Velasquez G, Boulet P. Globalization and Access to Drugs: Perspectives on the WTO/TRIPS Agreement (Revised). Geneva, World Health Organization, 1999. WHO/DAP/98.9.

34. VSO. Street Price. Making Medicines Affordable for Poor Countries. London, VSO, 2001.

35. Weisbrot M. Rich-Country Protectionism Puts WTO on the Slow Track. Third World Economics. Trends and Analysis, 2001, issue 268, no. 1.

36. WHO. Global Comparative Pharmaceutical Expenditures with Related Reference Information. Health Economics and Drugs, EDM Series No. 3. Geneva, World Health Organization, 2000. EDM/PAR/2000.2.

37. WHO. Globalization, Patents and Drugs. An Annotated Bibliography, 2nd ed. Health Economics and Drugs, EDM Series No 10. Geneva, World Health Organization, 2001. EDM/PAR/2001.1.

to previous section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017